TRACON Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
29.84 M |
Public Float |
22.05 M |
TRACON Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.13 |
Market Cap |
$18.54 M |
Shares Outstanding |
29.9 M |
Public Float |
20.61 M |
Address |
4350 La Jolla Village Drive San Diego California 92122 United States |
Employees | - |
Website | http://www.traconpharma.com |
Updated | 07/08/2019 |
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The company products include TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, TRC205 an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. |